Q3 2025 · 13F-HR
a16z Capital Management, L.L.C.holdings as filed
Filed 2025-11-14 · accession 0001540358-25-000007
$1.39B
Reported value
11
Positions
2025-09-30
Period end
The Brief · a16z Capital Management, L.L.C. · Q3 2025
AI · grounded in 13F
a16z Capital Management, L.L.C. established a new position in FIG valued at $842.7M. The fund also added META to its portfolio with a new investment of $156.1M. Additionally, the firm closed its entire position in OPEN, reducing its exposure by $3.3M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 316841105 | FIG | FIGMA INC | $842.7M | 60.4% | 16,246,129 | Common | SOLE |
| 30303M102 | META | META PLATFORMS INC | $156.1M | 11.2% | 212,531 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $128.4M | 9.20% | 2,748,523 | Common | SOLE |
| 68170A108 | OMDA | OMADA HEALTH INC | $102.0M | 7.31% | 4,614,574 | Common | SOLE |
| 852234103 | XYZ | BLOCK INC | $73.5M | 5.27% | 1,016,697 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $44.1M | 3.16% | 1,702,225 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $19.0M | 1.36% | 3,233,170 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $14.9M | 1.07% | 17,653,917 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $6.4M | 0.46% | 2,125,339 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $6.2M | 0.45% | 2,862,500 | Common | SOLE |
| 37611X209 | DNA | GINKGO BIOWORKS HOLDINGS INC | $1.6M | 0.11% | 108,568 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.